Aligos Therapeutics and Metrion explore key approaches to cardiovascular safety screening in drug discovery.
Presentation by Marc Rogers (Metrion CSO) at the September 2015 Safety Pharmacological Society, Prague. Using high quality HTS automated patch-clamp data from human cardiac ion channels and in silico action potential modelling to cost-effectively predict QP prolongation and arrhythmia risk for CiPA.
Aligos Therapeutics and Metrion explore key approaches to cardiovascular safety screening in drug discovery.
Academic case study on Nav1.9 as a drug target by Associate Professor David Bulmer (University of Cambridge). Overview of Metrion’s newly developed Nav1.9 screening assays by Metrion CSO, Dr. Eddy Stevens.